Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 8 art units • 13 examiners • 0 of 14 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
The Salk Institute for Biological Studies currently manages 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 14 actions are distributed across 8 distinct art units, reflecting a broad range of biological research. The prosecution involves 13 distinct examiners, which indicates that almost every pending case is being reviewed by a different individual.
BRETZ, COREY LANE is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. This count of 2 is the highest number of actions assigned to any single examiner in the group. With 13 distinct examiners for 14 pending office actions, the workload is highly distributed, with only BRETZ, COREY LANE handling more than one case.
The 8 distinct art units involved mean that the 14 pending office actions are subject to the standards of many different examination groups. Practitioners should note that they will be dealing with 13 different examiners, which may lead to a variety of prosecution experiences. The 2 pending office actions under BRETZ, COREY LANE represent the only point of examiner overlap in the current Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (14%) |
| §103 only | 1 (7%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 4 (29%) |
| Multi-statute (no §101) | 4 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| MEYER, GEORGE WILLIAM | 1 | 100.0% | +0.0% |
| CHATTERJEE, JAYANTA | 1 | 45.5% | +80.0% |
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| PRONZATI, GINA | 1 | 66.7% | +45.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | LIPPOLIS, ALEXANDRA ROSE | 125d overdue |
| 17104372 | TARGETED GENE ACTIVATION USING MODIFIED GUIDE RNA | RAVINDRA, KRISHNA NUGGEHALLI | 34d |
| 18954772 | IRON MAN (IMA) OVEREXPRESSION INCREASES DISEASE RESISTANCE | MEYER, GEORGE WILLIAM | — |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | — |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | — |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | — |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | BRETZ, COREY LANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 147d overdue |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | VANHORN, ABIGAIL LOUISE | 19d overdue |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | — |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | — |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | — |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | LEONARD, ARTHUR S | — |
| 17990489 | FLAVONE DERIVATIVES AND USES IN TARGETING CK2-MEDIATED DISEASES AND CONDITIONS | CHONG, YONG SOO | — |
| 17681538 | ADENOVIRAL ASSEMBLY METHOD | PRONZATI, GINA | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1662 | 2 |
| 1631 | 2 |
| 1636 | 2 |
| 1623 | 1 |
| 1633 | 1 |
| 1637 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18954772 | IRON MAN (IMA) OVEREXPRESSION INCREASES DISEASE RESISTANCE | MEYER, GEORGE WILLIAM | 1662 | §103§112 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18840877 | COMPOSITIONS AND METHODS FOR INCREASING PERIDERM IN PLANT ROOTS | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | GILL, RACHEL B | — | §101§103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18288772 | MULTIPLEX CRISPR/Cas9-MEDIATED TARGET GENE ACTIVATION SYSTEM | SHIN, DANA H | 1635 | §103§112DPOther | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | LEONARD, ARTHUR S | 1631 | §112 | Final Rejection | — | Pending | Apr 19, 2023 |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | VANHORN, ABIGAIL LOUISE | 1636 | §103DP | Final Rejection | 19d overdue | Pending | Apr 12, 2023 |
| 18151093 | RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION | BRETZ, COREY LANE | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17990489 | FLAVONE DERIVATIVES AND USES IN TARGETING CK2-MEDIATED DISEASES AND CONDITIONS | CHONG, YONG SOO | 1623 | §102Other | Final Rejection | — | Pending | Nov 18, 2022 |
| 17741311 | COMPOSITIONS AND METHODS FOR HIGH-EFFICIENCY RECOMBINATION OF RNA MOLECULES | BRETZ, COREY LANE | 1635 | §112DP | Non-Final OA | — | Pending | May 10, 2022 |
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 147d overdue | Pending | Apr 15, 2022 |
| 17681538 | ADENOVIRAL ASSEMBLY METHOD | PRONZATI, GINA | 1633 | DP | Final Rejection | — | Pending | Feb 25, 2022 |
| 17637058 | COMPOSITIONS AND METHODS FOR IN VIVO GENE EDITING | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102§103 | Final Rejection | 125d overdue | Pending | Feb 21, 2022 |
| 17104372 | TARGETED GENE ACTIVATION USING MODIFIED GUIDE RNA | RAVINDRA, KRISHNA NUGGEHALLI | 1636 | §103§112 | Final Rejection | 34d | Pending | Nov 25, 2020 |
| 18403664 | METHODS OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS | PATEL, SAGAR S | 1626 | §103 | Non-Final OA | — | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial